MilliporeSigma invests $47M in U.S. biomanufacturing facilities

By The Science Advisory Board staff writers

December 7, 2020 -- MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing facilities.

The expansions will increase capacity and output in 2021 (MA) and 2022 (NH) and create 700 new manufacturing positions. These sites will supply critical products to customers for the development and manufacturing of therapies, including COVID-19 vaccines.

MilliporeSigma's combined expansions are expected to create nearly 700 new jobs in New Hampshire and Massachusetts. Image courtesy of MilliporeSigma.

The Danvers expansion will add 65,000 sq ft of single-use assembly operations to the existing 120,000-sq-ft facility. This will support MilliporeSigma's Mobius single-use consumables production. The total investment in about $25 million and will add approximately 400 jobs throughout 2021.

The Jaffrey expansion will add 25,000 sq ft to the existing 260,000-sq-ft facility. The additional capacity will include new production lines and equipment and support production of filtration devices and membrane products, namely, Durapore filters, Express filters, and Viresolve products that are used to remove viral contamination during therapeutic production. The total investment in Jaffrey is $22 million and will bring 275 jobs by 2022.

MilliporeSigma holds topping-out ceremony for new membrane plant
MilliporeSigma celebrated the topping out of its new membrane production plant in Darmstadt, Germany, with a ceremony on October 8.
MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million...
MilliporeSigma, Baylor partnering on COVID-19 vaccine
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter